Literature DB >> 11209109

Chronic venous insufficiency and venous leg ulceration.

I C Valencia1, A Falabella, R S Kirsner, W H Eaglstein.   

Abstract

UNLABELLED: Venous ulcers are the most common form of leg ulcers. Venous disease has a significant impact on quality of life and work productivity. In addition, the costs associated with the long-term care of these chronic wounds are substantial. Although the exact pathogenic steps leading from venous hypertension to venous ulceration remain unclear, several hypotheses have been developed to explain the development of venous ulceration. A better understanding of the current pathophysiology of venous ulceration has led to the development of new approaches in its management. New types of wound dressings, topical and systemic therapeutic agents, surgical modalities, bioengineered tissue, matrix materials, and growth factors are all novel therapeutic options that may be used in addition to the "gold standard," compression therapy, for venous ulcers. This review discusses current aspects of the epidemiology, pathophysiology, clinical presentation, diagnostic assessment, and current therapeutic options for chronic venous insufficiency and venous ulceration. (J Am Acad Dermatol 2001;44:401-21.) LEARNING
OBJECTIVE: At the conclusion of this learning activity, participants should be familiar with the 3 main types of lower extremity ulcers and should improve their understanding of the epidemiology, pathogenesis, risk factors, clinical presentation, diagnostic assessment, and current therapies for chronic venous insufficiency and venous ulcers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11209109     DOI: 10.1067/mjd.2001.111633

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  66 in total

Review 1.  Hyperspectral imaging in diabetic foot wound care.

Authors:  Dmitry Yudovsky; Aksone Nouvong; Laurent Pilon
Journal:  J Diabetes Sci Technol       Date:  2010-09-01

2.  Designing clinical trials to bring wound products to market.

Authors:  Alejandra C Vivas; Andrea D Maderal; Martin P Than; Robert S Kirsner
Journal:  Int Wound J       Date:  2011-12-14       Impact factor: 3.315

3.  Dermacase. Chronic venous insufficiency.

Authors:  Irina Turchin; Benjamin Barankin
Journal:  Can Fam Physician       Date:  2006-10       Impact factor: 3.275

Review 4.  Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  [Evidence of compression therapy].

Authors:  W Konschake; E Valesky; H Stege; M Jünger
Journal:  Hautarzt       Date:  2017-08       Impact factor: 0.751

6.  Asperosaponin VI promotes angiogenesis and accelerates wound healing in rats via up-regulating HIF-1α/VEGF signaling.

Authors:  Cheng-Gui Wang; Yi-Ting Lou; Min-Ji Tong; Li-Lian Zhang; Zeng-Jie Zhang; Yong-Zeng Feng; Shi Li; Hua-Zi Xu; Cong Mao
Journal:  Acta Pharmacol Sin       Date:  2017-12-07       Impact factor: 6.150

7.  Hyaluronic Acid Sodium Salt 0.2% Gel in the Treatment of a Recalcitrant Distal Leg Ulcer: A Case Report.

Authors:  Mario Tagliagambe; Tuan A Elstrom; Daniel B Ward
Journal:  J Clin Aesthet Dermatol       Date:  2017-11-01

Review 8.  Nitric Oxide Therapy for Diabetic Wound Healing.

Authors:  Maggie J Malone-Povolny; Sara E Maloney; Mark H Schoenfisch
Journal:  Adv Healthc Mater       Date:  2019-01-15       Impact factor: 9.933

9.  Modified Unna Boot and Pinch Grafting for Chronic Non-healing Venous Leg Ulcer.

Authors:  D N Balaraju; Chakravarthi R Srinivas; Sanjay V Mukhi
Journal:  J Cutan Aesthet Surg       Date:  2008-01

10.  Evaluation of the bacterial diversity among and within individual venous leg ulcers using bacterial tag-encoded FLX and titanium amplicon pyrosequencing and metagenomic approaches.

Authors:  Randall D Wolcott; Viktoria Gontcharova; Yan Sun; Scot E Dowd
Journal:  BMC Microbiol       Date:  2009-10-27       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.